The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases

Babette L. R. Reijs*, Charlotte E. Teunissen, Nikolai Goncharenko, Fay Betsou, Kaj Blennow, Ines Baldeiras, Frederic Brosseron, Enrica Cavedo, Tormod Fladby, Lutz Froelich, Tomasz Gabryelewicz, Hakan Gurvit, Elisabeth Kapaki, Peter Koson, Luka Kulic, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleo, Walter Maetzler, Alexandre de MendoncaAnne-Marie Miller, Jose L. Molinuevo, Brit Mollenhauer, Lucilla Parnetti, Uros Rot, Anja Schneider, Anja Hviid Simonsen, Fabrizio Tagliavini, Magda Tsolaki, Marcel M. Verbeek, Frans R. J. Verhey, Marzena Zboch, Bengt Winblad, Philip Scheltens, Henrik Zetterberg, Pieter Jelle Visser

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
Original languageEnglish
Article number216
JournalFrontiers in Neurology
Publication statusPublished - 15 Oct 2015


  • biobank
  • cerebrospinal fluid
  • dementia
  • Alzheimer's disease
  • Parkinson's disease
  • neurodegenerative disorders
  • body fluids

Cite this